KINTOR PHARMA-B (09939) Plans to Issue 30.4875 Million Subscription Shares at 15.03% Discount, Raising Approximately HK$49.78 Million
Stock News
Nov 12
KINTOR PHARMA-B (09939) announced on November 12, 2025, that the company intends to issue 30.4875 million subscription shares to Huayuan Management Consulting (Hong Kong) Limited, wholly owned by China-Singapore Suzhou Industrial Park Venture Capital Co., Ltd. The subscription price is set at HK$1.64 per share, representing a discount of approximately 15.03% compared to the closing price of HK$1.93 per share on the last trading day on the Hong Kong Stock Exchange. The net proceeds from the subscription, amounting to approximately HK$49.78 million, will be allocated for the group's general working capital and the Phase III clinical trials of KX-826.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.